Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERCUTIO: MYK-224 in Obstructive Hypertrophic Cardiomyopathy
NCT05556343Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of BMS-986435 in hypertrophic cardiomyopathy (HCM), sponsored by Bristol Myers Squibb. Started Jan 2023; status: terminated.
02
Drugs
BMS-986435
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT05556343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05556343.